Rhode Island College

Digital Commons @ RIC
Master's Theses, Dissertations, Graduate
Research and Major Papers Overview

Master's Theses, Dissertations, Graduate
Research and Major Papers

5-1-2013

Prevention Management of Postoperative Nausea and Vomiting in
Ambulatory Setting: How Well are We Identifying Patients with
Motion Sickness?
Sheila A. Capasso
Rhode Island College

Follow this and additional works at: https://digitalcommons.ric.edu/etd
Part of the Nursing Commons

Recommended Citation
Capasso, Sheila A., "Prevention Management of Postoperative Nausea and Vomiting in Ambulatory
Setting: How Well are We Identifying Patients with Motion Sickness?" (2013). Master's Theses,
Dissertations, Graduate Research and Major Papers Overview. 217.
https://digitalcommons.ric.edu/etd/217

This Major Paper is brought to you for free and open access by the Master's Theses, Dissertations, Graduate
Research and Major Papers at Digital Commons @ RIC. It has been accepted for inclusion in Master's Theses,
Dissertations, Graduate Research and Major Papers Overview by an authorized administrator of Digital Commons
@ RIC. For more information, please contact digitalcommons@ric.edu.

PREVENTION AND MANAGEMENT OF POSTOPERATIVE NAUSEA AND
VOMITING IN AMBULATORY SETTING: HOW WELL ARE WE IDENTIFYING
PATIENTS WITH MOTION SICKNESS?

By
Sheila A. Capasso RN, BSN, CAPA
A Major Paper Submitted in Partial Fulfillment
Of the Requirements for the Degree of
Master of Science in Nursing
in
The School of Nursing
Rhode Island College
2013

Abstract
Postoperative nausea and vomiting (PONV) and postdischarge nausea and vomiting
(PDNV) continue to be a serious problem in the ambulatory setting. These symptoms are
among the most undesired complications following surgery and can adversely affect the
quality of recovery for many patients. Previous research has concluded that the
identification of risk factors for PONV/PDNV is a first step in developing effective
prevention strategies. The purpose of this study was to examine the incidence of PONV/
PDNV in the ambulatory setting in female clients who were treated with transdermal
scopolamine (TDS) for motion sickness as compared to those patients who were not
treated with TDS. The study design was a two-group retrospective chart review. Of the
group identified with a positive history and not treated with TDS, 54% (n=6) developed
PONV /PDNV as compared to 26% (n=3) that were treated. This pilot study provided
preliminary support that preoperative identification of PONV/PDNV risk factors and
treatment with TDS reduces PONV/PDNV. Standardized, comprehensive risk factor
identification in the preoperative period is indicated.
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Prevention and Management of Postoperative Nausea and Vomiting in Ambulatory
Surgery: How Well Are We Identifying Patients with Motion Sickness?

Background / Statement of Problem
Postoperative nausea and vomiting (PONV) is a serious problem in the ambulatory
surgical setting. Identified as a surgical problem since 1848, after the introduction of
anesthesia, PONV is one of the most undesired complications following surgery.1 One
third of all patients requiring anesthesia for surgery will develop PONV, and as many as
30% to 50% of outpatients will develop postdischarge nausea and vomiting (PDNV) after
their arrival home.2 From 1996 to 2006, the number of outpatient surgery visits in the
United States (US) increased from 20.8 to 34.7 million, accounting for half of all
surgeries .3 With the increasing number of outpatients surgeries, PDNV will also
increase, making the identification of risk factors and preventing PONV and PDNV an
important factor in the saftey and satisfaction of these patients.

PONV encompasses three main symptoms, nausea, vomiting and retching, which may
occur separately or in combination after surgery.4 Each vomiting episode delays
discharge from recovery room by 25 minutes.5 It is estimated that approximately 0.2% of
all surgical patients may experience intractable PONV, leading to delays in discharge
from recovery areas and unanticipated hospital admissions following ambulatory
surgery.6
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A history of motion sickness or prior PONV are considered independent predictors for
PONV, likely because the patient has already established a reflex arc for vomiting.7
Motion sickness is a syndrome that occurs in response to a real or perceived motion.8
Early assessment and treatment of patients at risk for PONV before surgery, including
those with a history of motion sickness, can minimize negative outcomes. The purpose of
this study was to examine the incidence of PONV/ PDNV in the ambulatory setting in
female clients treated with transdermal scopolamine for motion sickness as compared to
those patients who are not treated with scopolamine.

Literature Review
The processes of nausea, vomiting, and retching are coordinated by the vomiting center
in the brain.9 Nausea is a subjective and unpleasent sensation that is associated with the
urge to vomit. Vomiting and retching are objective patient experiences; vomiting
(emesis) includes the forceful expulsion of gastric contents from the mouth, and retching
represents an unproductive effort to vomit.10 Stimulation of these processes can be
initated from the periphery and centrally from the CNS. Stimuli are relayed from the
periphery to the vomiting centre by the autonomic nervous system afferent neurons of the
vagus nerve. There is afferent input to the area postrema from the vagal and
glossopharyngeal nerves. Central cerebral sensory stimuli occur directly and are
transmitted by the chemoreceptor trigger zone (CTZ) area postrema, and nucleus of the
solitary tract in the lateral reticular formation of the medulla to the vomiting centre.
Chemicals in the CSF and blood have a direct stimulating effect at the vomiting centre.9
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The areas in the CNS associated with balance, vasomotor activity, salivation, respiration
and bulbar control are located near, and have innervations to, the vomiting centre. The
close proximity of these areas to the vomiting centre corresponds to the physiological
reactions seen in PONV, such as tachypnea, tachycardia, sweating, increased swallowing,
cardiac dysrhythmias, and motion sickness. 9

Postoperative nausea and vomiting occur after 25% to 30% of surgeries and significantly
contribute to patients’ discomfort, distress, and dissatisfaction .9 Among high-risk
patients, the incidence of PONV can be as high as 70%.11 The most common of
postsurgical complications, PONV and PDNV affect approximately 25 million patients
worldwide yearly with an estimated financial impact of several million dollars.12,13 The
incidence of PDNV is more difficult to document due to lack of reporting, but it has been
estimated that one-third of patients will experience PDNV after discharge from
ambulatory setting.2 With more than 60% to 65% of surgeries performed in an
ambulatory setting, PDNV is a significant problem affecting thousands of patients .2 Until
recently, there has been no clear definition of PDNV, although the term is related to
discharge of a patient after ambulatory surgery. A strategic work team, convened by
American Society of PeriAnesthesia Nurses (ASPAN), distinguished PDNV from PONV.
PDNV was defined as nausea or vomiting that occurs after discharge from a surgical
facility, while PONV was identified as occurring within the first 24 hours of surgery.14
The question as to whether the person who is nauseated or has emesis during transport
home is diagnosed with PONV or PDNV remains. 15
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Despite the use of prophylactic antiemetics for preventing PONV, many surgical patients
undergoing general anesthesia still experience PONV in the post anesthesia care unit, the
hospital, and at home after discharge.16 ASPAN developed practice guidelines designed
to assist the practitioner to identify high-risk patients and develop a multimodal plan of
treatment; risk factors were identified as surgery related, anesthesia related, and patient
related.14 Surgery related factors that increase risk include type of surgery, length of
surgery, and anesthesia techniques used. Surgeries that have a direct relationship on
increased incidence of PONV include eye, oral, plastic, ear, nose and throst, head and
neck, gynecological, obstetric, laproscopic and abdominal procedures.17 Longer
operations (greater than three hours) allow for longer exposure to lipid soluble,
potentially emetic intravenous, and inhalation gas anesthetics, all of which can cause an
increase in PONV.18

Compared with a purely regional anesthetic technigue, general anesthesia is associated
with a significantly higher incidence of nausea, vomiting, and overall PONV.19 This fact
raises the question as to the contribution of the drugs used during surgery. There have
been several meta-analysis that have shown decreased nausea and vomiting when
propofol is used as opposed to inhalation agents. 20,21,22 Some anesthetic agents increase
the risk of PONV. Apfel and colleagues conducted a large clinical trial of 5199 patients.
Each patient had at least a 40% risk of PONV according to a simplfied risk score, based
on the presence of at least two risk factors. This trial simultaneously evaluated
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antiemetic efficacy and anesthetic interventions. All the tested antiemetics appeared
similarily effective; substituting propofol for a volatile anesthetic reduced the rate of
PONV by 19%, whereas substituting nitrogen for nitrous oxide reduced the risk by 12%.
Combining these two anesthetic strategies ( total intravenous anesthesia) reduced the risk
by as much as any single antiemetic. In a trial comparing nitrous oxide group with an
oxgen enriched air group, Myles et al.23 found that the group receiving nitrious oxide had
significantly more severe adverse events, including pulmonary complications, wound
infections, and fever; the oxgen enriched air group had lower rates of severe nausea and
vomiting.

Patient specific risk factors for PONV/ PDNV include female gender, non-smoking
status, and the use of opioids for postoperative analgesia, motion sickness, or previous
PONV.10,16, 24 Nonsmokers are at higher risk of development of PONV than smokers.7
Chatterjee et al. 6 identified that chronic exposure to smoke, in particular polycyclic
aronmatic hydrocarbons, produced changes in liver microsomal enzymes that may
change the metabolism of drugs used in the peri-operative period and the capicity of these
drugs to produce PONV.6 There is a three fold increase in the incidence of PONV in
patients who have a history of PONV or motion sickness.4 A history of motion sickness
or prior PONV/PDNV are considered independent predictors of PONV.7

Motion sickness is a syndrome that occurs in response to real or perceived motion, and
includes gastrointestinal, central nervous system, and autonomic symptoms.8 Motion
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sickness occurs following stimulation of the vestibular apparatus of the inner ear;
following this stimulation, transmission of impulse to the CTZ and vomiting centre
occurs, relaying to the CNS the sensation of nausea and motion sickness. Vomiting may
then occur. Characteristics that show some correlation to motion sickness are sex, age,
hormonal factors, disease that alter vestibular or visual sensory cues, and migraine .8
Physical signs of motion sickness include sense of dizziness, nausea, belching, increased
salavation, warmth, and diaphoresis, along with a feeling of malaise.8 In two independent
investigations, Cheung et al. 25 found no effect of menstrual cycle on motion sickness,
whereas Golding et al. 26 found an increased susceptibility to motion sickness.,27
Accurate assessment of motion sickness and effective treatment are key.

Knowledge of risk factors is essential for the identification of high-risk patients and
effective multimodal management of PONV.28 Several risk assessment tools have been
developed using multiple regression analysis to identify factors that are strong
independent predictors of PONV.28 Palazzo and Evans, 29 Koivuranta et al.,30 and Apfel
et al.24 each developed risk assessment tools. Each tool included the same five variables
in the risk score, including female gender, nonsmoking status, history of PONV, history
of motion sickness, and postoperative use of opioids .28 The Apfel model has been
successfully used to predict which patients are likley to develop PONV.12 On the basis of
the Apfel et al.12 risk scoring system, a female patient who has had a history of PONV
and is receiving opioids for pain has a 60% chance of developing PONV.31
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It is recommended that any risk model must undergo external validation before it can be
used in clinical practice.10 Given the limitations in validating PONV risk factors, it is not
surprising that scoring systems have shown only poor to moderate accuracy. Despite the
limitations, their use to better tailor antimetic interventions has been shown to
significantly reduce the incidence of PONV particularly in high risk patient populations.10
The prediction of PONV/PDNV relies on the assessment of the patient, and places
emphasis on how well the evaluation is completed. In a review done by Eberhart &
Morin, risk score assessment was found to be a useful tool to predict PONV, though
anaesthesiologists tend not too use them.32 Criticism of the general application of PONV
scores is based not only on the systematic lack of external validation of the scores but
also on other methodological issues.32

Clinical practice guidelines for managing PONV and PDNV have been developed by the
American Society of Anesthesiologists (ASA),33 the American Society of Perianesthesia
Nurses (ASPAN),14 and the Society of Ambulatory Anesthesia (SAMBA).13 ASA
guidelines provide an evidence-based reference tool for anesthesia providers in the
management of patients at risk for PONV/PDNV.33 The ASA guidelines include: risk
factor identification for PONV using the simplified Apfel et al.24 risk factor assessment
tool; recommendations to reduce the baseline risk for PONV and identify the optimal
approach to PONV prevention and therapy; guidelines to determine the choice and timing
of antiemetic administration; and identify the most effective monotherapy and
combination therapy.33
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Antiemetic medications are the most common treatment for PONV. Because there is no
single receptor or stimulus for PONV, no one amtiemetic will be effective in all
patients.31 In 2007, SAMBA revised ASA guidelines and made recommendations for
treating PONV/PDNV to include transdermal scopolamine (TDS) as one of the first and
second line antiemetic for use in motion sickness.12 In 2001, the US Food and Drug
Administration approved the use of transdermal scopolamine (TDS) for the prevention of
PONV. TDS is a long acting prophylactic antiemetic initially developed to prevent
motion sickness; it is a centrally acting anticholinergic agent.34 Scopolamine is an
effective preoperative antiemetic; it crosses the blood brain barrier and blocks cholinergic
stimulation of the vomiting center from both the gastrointestinal tract and the vestibular
center. TDS has been shown to be associated with significant reductions in PONV with
both early and late patch application during the first 24 hours after the start of
anesthesia.34 Anesthesia departments play a key role in promoting the adherence to
guidelines by monitoring the incidence of PONV and instituting policies that align with
current recommendations. 35

ASPAN organized an Evidence Based Practice Strategic Work Team (SWT) consisting
of 16 multi-disciplinary, multi-specialty experts to review published evidence related to
the prevention and/or management of PONV/PDNV. The guidelines apply to both
inpatient and outpatient settings and to procedures performed in the operating room, as
well as in other locations where sedation and anesthesia may be given.14
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Recommendations included prophylactic treatment of PONV based on the patients’ level
of risk, determined by risk factor assessment. Simplified risk factor tools establish the
patients’ baseline risk for PONV, and the number of interventions based on the level of
risk. 12ASPAN included the simplified risk factors tools as developed by Apfel et al.24
and Koivuranta et al.30 to establish the patient’s baseline risk for developing PONV. 14
Prophylactic recommendations include anesthesia related (total intravenous anesthesia
TIVA), pharmacologic therapeutic (hydration, and pain management), and
complementary interventions (acupoint). 14 In addition to pharmacologic agents
recommened by ASA, PONV prophylaxis, H1 receptor blockers (antihistamines) and the
scopolamine patch were recommend in the case of patients with motion sickness. 14

Conceptual Model
The Symptom Management model was used to guide this research; the model was
developed in 1994, by the University of California, San Francisco (UCSF) Symptom
Management Team and revised in 2001 to include broad based symptom management.36
A symptom is a subjective experience, reflected in the bio-psychosocial functioning,
sensations, or cognition of an individual,36 as compared to a sign, which is defined as any
abnormality indicative of disease that is detectable by the individual or by others. 36 The
UCSF model includes signs when needed to assess disease status and to evaluate and
verify the effectiveness of management strategies. 36 The Symptom Management Model
is based on the premise that effective management of any given symptom or group of
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symptoms demands that all three dimensions be considered: the interrelatedness of the
symptom experience; symptom management strategies; and outcomes.

The revised model recognizes the domains of nursing science, person, health/illness and
environment, which influence the three dimensions. The symptom experience includes an
individual’s perception of the symptom, evaluation of the meaning of the symptom, and
response to a symptom. The goal of symptom management is to avert negative outcomes,
and begins in the assessment phase of the symptom experience, followed by identifying
and focusing on intervention strategies. Interventions are targeted at one or more
components of the individual’s symptom experience to achieve desired outcomes.36
Although the physiology of the vomiting center is understood; the pathways to control
nausea and vomiting are not well defined.36

Method
The purpose of this study was to examine the incidence of PONV/PDNV in the
ambulatory setting in female clients who were treated with TDS for motion sickness as
compared to those who were not treated with TDS.
Research Design
The study was designed as a two-group retrospective chart review; the groups included a
convenience sample of 156 female clients. Group 1 included those female clients who
were identified as having a previous history of PONV/PDNV or motion sickness and
were treated with TDS; Group 2 included females with a history of motion sickness who
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were not treated with TDS. The hypothesis was that patients identified with a previous
history and/or motion sickness and treated with TDS preoperatively would have a
decreased rate of PONV/PDNV, as opposed to those who were not treated with TDS.
Site
This study was conducted at The Fain Health Center, an ambulatory surgical unit at The
Miriam Hospital, Providence R.I. The Fain Health Center provides care to clients
undergoing ambulatory surgery.
Sample
Inclusion criteria included those female clients 17 years or older who had received
general anesthesia for laproscopic, gynecological, or breast surgery and had been
identified as having a history of PONV/PDNV or motion sickness , either through
preoperative nursing assessment or through anesthesia assessment, and were either
treated with TDS or not treated with TDS. Exclusion criteria included those who met
inclusion critera but had received emetrogenic or antiemetic drugs within the 24 hours
prior to surgery, as well as clients for whom TDS was contraindicated.
Procedures
Prior to data collection, permission was obtained from the Lifespan and Rhode Island
College Institutional Review Boards (IRB). Institutional permission was also obtained
from the Director of Surgical Services. After approval, the student investigator obtained a
list of clients from the surgical schedule whose surgeries occurred between January and
October 2012. The list was submitted to health information services via a medical record
request form, and requested records were retrieved by the health information staff. Once
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retrieved, the student investigator reviewed records for the identified inclusion/
exclusion criteria.
The student investigator extracted relevant data, using a data collection tool developed
from the literature review and clinical experience (Appendix A). The focus of the tool
was on risk factors for PONV/PDNV as well as anti-emetics used and use of TDS.
Documentation reviewed included the preadmission assessment form, anesthesia
assessment form, and the pre-procedure verfication form.
Data Analysis
Descriptive statistic techniques were used to summarize findings. Differences between
groups related to PONV/PDNV were examined.

Results
A total of 180 records were reviewed; 24 were not included because those clients had
received modified anesthesia as compared to general anesthesia. Prophylactic antiemetics
administered to all clients intraoperatively included dexamethasone 4mg (Decadron) and
ondansetron 4mg (Zofran). Data from remaining records (n=156) were then further
examined to identify those in which a history of PONV/PDNV or motion sickness was
identified, typically during the preadmission interview or when interviwed by the
anesthesiologist the day of surgery. A total of 26 clients (17%) were identified as having
a history of PONV/PDNV or motion sickness. The characteristics of the 26 clients are
illustrated in Table 1.
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Table 1
Risk Characteristics of Clients Identified with PONV/PDNV or Motion Sickness
Total Clients
Identified with
PONV/PDNV or
Motion Sickness
(n = 26; 16.6%)
Smoking Status
Never
Former
Current
Type of surgery
Laproscopic
Breast
Gynecological

Treated with
TDS
n =15 (58 %)

Not
Treated with
TDS
n =11 (42%)

n= 22 (85%)
n=3 (11%)
n=1 (5%)

n= 15 (100%)
n =0
n =0

n = 7 (73%)
n = 3 (18%)
n = 1 (9%)

n=12 (46%)
n=13 (50%)
n=1 (4%)

n = 6 (40%)
n = 8 (53%)
n =1 (7%)

n = 6 (55%)
n = 5 (45%)
n=0

The age range of clients was from 17 to 75 with a mean of 44.2 years. The majority of the
sample were non smokers (n=22; 85%) and half had undergone breast procedures (n =
13).

The remaining 130 medical records (83%) included no documentation as to whether there
was a history of PONV/PDNV or motion sickness. None of these forms have a specific
area for documentation of risk factors, and only the preadmission form had a question
asking if the client or family members had any difficulty with anesthesia. The client
recruitment breakdown is illustrated in Figure 1.
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Figure 1. Distrubution of PONV/PDNV

Twenty six clients (17%) identified having a history of PONV/PDNV or motion sickness.
Of those 26, 15 (58%) were treated with TDS, while 11 (42%) were not treated. Of those
that were treated with TDS (n =15), 26% (n= 3) developed PONV/PDNV as compared
to those with a history of PONV/ PDNV or motion sickness (n =11) and not treated
(n=6; 54%). In the group without documentation related to whether a history of
PONV/PDNV or motion sickness existed (n=130), 48 ( 37%) developed PONV/PDNV.

Discussion
The purpose of this study was to examine the incidence of PONV/ PDNV in the
ambulatory setting in female clients who were treated with TDS for motion sickness as
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compared to those clients who were not treated with TDS. PONV/PDNV continues to be
a significant problem despite the use of antiemetics and negatively affect patients’ quality
of recovery and patient satisfaction. In this study, when a history of PONV/ PDNV or
motion sickness was identified and treated with TDS, PONV/ PDNV were reduced as
compared to when not treated with TDS (26% versus 54% respectively).

Guidelines have been developed by ASA, 33 ASPAN, 14 and SAMBA 13 to assist
clinicians with an evidence-based, practical approach to the prevention and/ or
management of PONV and PDNV. These guidelines were developed to serve as a
resource to anesthesia providers and perianesthesia nurses involved in the care of patients
at risk for PONV/ PDNV.14 Although these guidelines serve as a tool for the management
of PONV, they also suggest that not all patients will benefit from antiemetic prophylaxis,
and that the identification of patients who are at increased risk leads to the most effective
use of therapy.4 This study provided supportive evidence that preoperative identification
of risk factors and treatment with TDS can potentially reduce PONV/PDNV.

Limitations
Given that this was a retrospective design, the information retrieved from records was
limited to what was documented. Results of the study may have been affected by certain
variables that were not controlled for including the use of volatile anesthetics, and
postoperative use and administration of opioids. This study was limited by a small sample
size and the limited amount of demographic data that was collected.
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Recommendations for Practice
Nausea and vomiting are commonly feared by surgical patients, and remain the source of
significant anxiety for patients and families. PONV/PDNV also has the potential to
negatively impact patient outcomes, and can result in increased length of stay for the
patient and the institution. Prevention of PONV/PDNV is a high priority for nurses in the
perianesthesia setting; when prevention is not possible, effective treatment is the primary
goal. Reliable and valid risk assessment tools are available for use in clinical settings,
and recommended for use by ASA and ASPAN. Consistent use of a risk assessment tool
to identify risk factors for PONV/PDNV before surgery is recommended.

Conclusions
In spite of the advances made in anesthesia and in management of post-operative
symptoms, PONV/ PDNV continue to be a problem for surgical patients. Kapur referred
to PONV as the “big little problem”.37 Identification of high-risk patients is essential to
the prevention of PONV/PDNV. The Symptom Management Model guided this research
and is based on the assumption that the symptom does not have to be experienced by an
individual for the individual to be at risk for the development of the symptom. 36 It is
easier to treat nausea and prevent vomiting than to stop vomiting once it has started.1
Collaboration and communication of risk factors between the anesthesia team and
nursing staff members must occur in order to bring best practices to the patient. Accurate
identification of PONV/PDNV risk factors in the interdisciplinary treatment plan is an
essential first step; perianesthesia nurses are positioned to obtain an accurate assessment
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of patient risk for PONV/ PDNV. The integration of a Clinical Nurse Specialist (CNS) to
the perianesthesia team would assist the nurses in problem identification, critique, and
review of the literature, as well as in the design and implementation of practice changes
to improve patient outcomes. The CNS is trained to work within and across the patient,
nursing, and systems /organizational spheres, and plays a major role in impacting policy.
The CNS needs to work to assure that existing guidelines and policies related to
prevention of PONV / PDNV are implemented and continuously evaluated. The
reduction of PONV/ PDNV rates through the use of standardized risk factor assessment
tool can positivity increase patient satisfaction and improve patient outcomes. National
adoption will better assure that clinical prevention and population health objectives are
met.
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Appendix A
Researcher-Developed Data Collection Tool
Age	
  

Race	
  

Smoking	
  

History	
  

History	
  

Anesthesia	
  

	
  

Number	
  of	
  

Use	
  of	
  	
  

History	
  

of	
  

of	
  

Type	
  

Type	
  of	
  Surgical	
  Procedure	
  

Antiemetic	
  

Scopolamine	
  

PONV	
  

Motion	
  
Sickness	
  

Laparoscopic	
  

Breast	
  

GYN	
  

	
  

PONV= Postoperative Nausea and Vomiting; PDNV= Post Discharge Nausea and
Vomiting; GYN= Gynecological
.
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